Clinical Trial Update: A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD [Phase 3]

View source ↗

Summary

Phase 3 safety trial evaluating revefenacin and formoterol, alone, sequentially, and in combination, in COPD patients; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Formoterol (formoterol)
• Revefenacin (revefenacin)

Snippet

Sponsor: Mylan Inc. | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Status: COMPLETED | Results posted: 2019-12-18